Your browser is not supported.

To view this content, please use one of the following browsers:

  • Microsoft Edge
  • Chrome
  • Safari
  • Home
  • Resources
  • Articles
  • CREDENCE trial: Effects of canagliflozin on heart failure and CV death

CREDENCE trial: Effects of canagliflozin on heart failure and CV death

CREDENCE trial: Effects of canagliflozin on heart failure and CV death

In the Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) trial, canagliflozin demonstrated a risk reduction for hospitalisation for heart failure (HHF) or cardiovascular (CV) death by 31% (HR 0.69, 95% CI 0.57-0.83, P=0.0001). In this paper the authors explore the effect of canagliflozin on HHF/CV death stratifying the CREDENCE population according to different clinical characteristics.

The analysis showed that the positive impact of canagliflozin is consistent across subgroups regardless of the baseline characteristics such as age, sex or co-morbidities, including renal function and CV disease history.

The absolute benefit of canagliflozin was greatest for patients with the highest baseline risk, such as those with CV disease or advanced renal disease.

  • For those with CV disease: 50 fewer events/1000 patients treated over 2.5 years vs. 20 fewer events in those without CV disease
  • For those with advanced renal disease of estimated glomerular filtration rate (eGFR) 30–45 mL/min/1.73m2: 61 events prevented/1000 patients treated over 2.5 years vs. 23 events in eGFR 60–90 mL/min/1.73m2.

The benefit of canagliflozin use across a broad spectrum of patient subgroups should provide clinicians confidence when prescribing canagliflozin to their patients.

Prescribing information for Invokana (canagliflozin)

T2DM Logo

Napp brings you recent and clinically relevant publications in the evolving field of Type 2 diabetes recommended by an international panel of specialists.

Editorial Board

Image
Dr. Salvatore A. De Cosmo's image

Dr. Salvatore A. De Cosmo

Head of Unit of Internal Medicine and Endocrinology, Scientific Institute “Casa Sollievo della Sofferenza” San Giovanni, Rotondo, Italy
,
Image
Dr. Juan José Gorgojo Martínez's image

Dr. Juan José Gorgojo Martínez

Head of Department of Endocrinology and Nutrition, University Hospital Fundación, Alcorcon, Madrid, Spain
,
Image
Dr. Patrick Holmes' image

Dr. Patrick Holmes

General Practitioner, St. George's Medical Practice, Darlington, UK

Editorial Board

Image
Dr. Salvatore A. De Cosmo's image

Dr. Salvatore A. De Cosmo

Head of Unit of Internal Medicine and Endocrinology, Scientific Institute “Casa Sollievo della Sofferenza” San Giovanni, Rotondo, Italy
Image
Dr. Juan José Gorgojo Martínez's image

Dr. Juan José Gorgojo Martínez

Head of Department of Endocrinology and Nutrition, University Hospital Fundación, Alcorcon, Madrid, Spain
Image
Dr. Patrick Holmes' image

Dr. Patrick Holmes

General Practitioner, St. George's Medical Practice, Darlington, UK

Publication under Spotlight

The Effects of Canagliflozin on Heart Failure and Cardiovascular Death by Baseline Participant Characteristics: Analysis of the CREDENCE Trial

Diabetes Obes Metab.
2021;23(7):1652-1659

Authors:Clare Arnott, Jing-Wei Li, Christopher P Cannon, Dick de Zeeuw, Brendon L Neuen, Hiddo JL Heerspink, David M Charytan, Anubha Agarwal, Mark D Huffman, Gemma A Figtree, George Bakris, Tara I-Hsin Chang, Kent Feng, Norman Rosenthal, Bernard Zinman, Meg J Jardine, Vlado Perkovic, Bruce Neal and Kenneth W Mahaffey

READ MORE